Anzalone Christopher Richard's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 16, 2025
- Accession no.
- 0001423029-25-000003
- Filed
- Dec 16, 2025
- Trade date
- Dec 12-16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 13 non-derivative transactions and 0 derivative transactions. Open-market sales total $12.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anzalone Christopher RichardCIK 0001423029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Common Stock | AGrant or awardAcquired | +180,000 | $0.00 | $0 | 4,101,255 | Direct | |
| Dec 15, 2025 | Common Stock | SSaleDisposed | −100,532 | $68.67 | −$6,903,532.44 | 4,000,723 | Direct | |
| Dec 15, 2025 | Common Stock | SSaleDisposed | −21,321 | $69.28 | −$1,477,118.88 | 3,979,402 | Direct | |
| Dec 15, 2025 | Common Stock | SSaleDisposed | −8,147 | $69.96 | −$569,964.12 | 3,971,255 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −8,416 | $60.51 | −$509,252.16 | 3,962,839 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −10,963 | $61.25 | −$671,483.75 | 3,951,876 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −14,095 | $62.12 | −$875,581.4 | 3,937,781 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −8,476 | $62.94 | −$533,479.44 | 3,929,305 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −6,661 | $64.29 | −$428,235.69 | 3,922,644 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −1,000 | $64.96 | −$64,960 | 3,921,644 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −1,300 | $65.77 | −$85,501 | 3,920,344 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −166 | $66.77 | −$11,083.82 | 3,920,178 | Direct | |
| Dec 16, 2025 | Common Stock | SSaleDisposed | −3,221 | $67.87 | −$218,609.27 | 3,916,957 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.